Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/17/2005US20050256171 Pyrrolidine derivatives as tryptase inhibitors
11/17/2005US20050256170 EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders
11/17/2005US20050256169 Nitric oxide scavengers
11/17/2005US20050256168 Compositions for oral administration for the treatment of interferon-responsive disorders
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256166 Nitrogen-containing compounds
11/17/2005US20050256165 For modulating sleep; sleep disorders such as sleep apnea or insomnia
11/17/2005US20050256164 NK1 and NK3 antagonists
11/17/2005US20050256163 Crystalline forms of fexofenadine hydrochloride and processes for their preparation
11/17/2005US20050256162 Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
11/17/2005US20050256161 Melanin concentrating hormone receptor antagonists
11/17/2005US20050256159 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
11/17/2005US20050256158 PGD2 receptor antagonists for the treatment of inflammatory diseases
11/17/2005US20050256157 Combination therapy with CHK1 inhibitors
11/17/2005US20050256156 Processes for preparing montelukast sodium
11/17/2005US20050256155 e.g. (3S,4aR,6R,8aR)-6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester trifluoroacetate salt; are substantially converted to the parent monoacid in the patient; AMPA glutamate receptor antagonists
11/17/2005US20050256154 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
11/17/2005US20050256153 Thienopyridinone compounds and methods of treatment
11/17/2005US20050256152 Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations
11/17/2005US20050256150 Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols
11/17/2005US20050256149 Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
11/17/2005US20050256148 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; parasitic or viral infections
11/17/2005US20050256147 Neuroprotective properties of dextrorotatory morphinans
11/17/2005US20050256146 Alpha-7 nicotinic receptor agonists and stains in combination
11/17/2005US20050256145 Pyrimidine derivatives for the treatment of abnormal cell growth
11/17/2005US20050256144 Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); anticancer agents; N-{1-[2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-yl]-piperidin-4-yl}-methanesulfonamide for example
11/17/2005US20050256143 Purine nucleosides
11/17/2005US20050256142 New purine derivatives
11/17/2005US20050256141 Remedies for glomerular diseases
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256139 Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2H-indol-2-one hydrochloride) and processes to produce the same
11/17/2005US20050256137 Pyridone compounds as inhibitors of bacterial type III protien secreation systems
11/17/2005US20050256136 1-[2-(3-Ethyl-ureido)-3H-benzoimidazol-5-yl]-1H-imiazole-4-carboxylic acid methyl ester; bacteriostatic antibiotic; decrease antibiotic resistance of bacterial organisms; new class of compounds for bacterial infections
11/17/2005US20050256135 inflammatory, allergic, respiratory diseases; increased Histamine H3 receptor potency and reduced cardiovascular side effects; 1,6-naphthyridines or 1,7-naphthyridines; 6-pyrimidin-2-yl-2-(3-pyrrolidin-1-ylpropoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine
11/17/2005US20050256134 Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
11/17/2005US20050256132 Use of ER selective NF-kB inhibitors for the treatment of sepsis
11/17/2005US20050256131 Pharmaceutical active substance combination and the use thereof
11/17/2005US20050256130 Substituted piperazines
11/17/2005US20050256129 treating disorders of the outer retina with compounds with 5-HT1A agonist activity; age-related macular degeneration
11/17/2005US20050256128 N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide; tuberculosis including multi-drug resistant and/or latent tuberculosis; antitubercular drugs
11/17/2005US20050256127 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
11/17/2005US20050256125 Selective inhibitors of certain receptor and non-receptor tyrosine kinases such as FAK (focal adhesion kinase); N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-4-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyrazin-2-yl)-methanesulfonamide for example; use with other antitumor agents
11/17/2005US20050256124 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
11/17/2005US20050256123 Heterocyclic inhibitors of MEK and methods of use thereof
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256121 Substituted 2,5-heterocyclic derivatives
11/17/2005US20050256120 Heterocyclo-substituted imidazoles for the treatment of inflammation
11/17/2005US20050256119 selective serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenocptor antagonist activity; To treat anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia without being sedative
11/17/2005US20050256118 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256116 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof
11/17/2005US20050256115 Aerosol formulation for the inhalation of beta-agonists
11/17/2005US20050256114 substituted 4H-benzo[1,4]oxazin-3-one derivatives, having antagonistic activity at muscarinic receptors and agonistic activity at adrenergic receptors; chronic obstructive pulmonary disease; asthma; bronchitis; adult respiratory distress syndrome
11/17/2005US20050256113 Anti-cytokine heterocyclic compounds
11/17/2005US20050256112 Enhancing the serotonergic neurotransmission; side effects reduction; nervous system disorders; sexual disorders; analgesics; antidepressants; anticancer; anxiolytic agents; neurodegenerative diseases; gastrointestinal tract disorders; eating disorders
11/17/2005US20050256111 Pyrimidine derivatives for the treatment of abnormal cell growth
11/17/2005US20050256110 Cyanopyrroles
11/17/2005US20050256109 HIV integrase inhibitors: cyclic pyrimidinone compounds
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256105 Protease inhibitors
11/17/2005US20050256104 Protease inhibitors
11/17/2005US20050256103 Indole derivative having piperidine ring
11/17/2005US20050256102 Inhibit Aurora kinase; cancer; 4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-methylamino-ethyl)-benzamide; 9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine
11/17/2005US20050256100 Protease inhibitors
11/17/2005US20050256099 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
11/17/2005US20050256098 CGRP receptor antagonists
11/17/2005US20050256097 Pharmaceutical solution formulations containing 17-AAG
11/17/2005US20050256095 using 6-bromo-3-hydroxtandrostan-17-one
11/17/2005US20050256094 especially those of the 20-spiroxane series; 11,12-epoxy steroid, 4,5-9,11-diepoxy steroid and 12-keto intermediates; Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,?-lactone, methyl ester, (7a,11a,17a)-; eplerenone or epoxymexrenone; minimum of isolation steps
11/17/2005US20050256093 Branched polyamine steroid derivatives
11/17/2005US20050256092 Antipsoriatic agent
11/17/2005US20050256090 Comprises as an active ingredient a sulphostin-related compound such as 3(S)-amino-1-((S)-amino(sulfoamino)-phosphinyl)-2-piperidone
11/17/2005US20050256088 condensates of an N-hydroxylamine and pyridoxal, pyridoxal phosphate, and heme-A, or a pharmaceutical salt thereof, and an excipient; prodrugs for releasing hydroxyamines for treating reverse age-related oxidative changes, delay senescence, and reverse mitochondrial decay; neuroprotective agents
11/17/2005US20050256087 Phosphonic acid diester compounds
11/17/2005US20050256086 Fosinopril formulation
11/17/2005US20050256084 Administering stachyose to treat atopic dermatitis; can be added to medicine, food and beverage
11/17/2005US20050256083 Preserved pharmaceutical compositions comprising cyclodextrins
11/17/2005US20050256082 Allergen inactivator
11/17/2005US20050256081 Tetracycline derivatives for the treatment of ocular pathologies
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256078 Hepatitis C; toxicity, side effects reduction; improved pharmacological/pharmacokinetics properties; novel intermediates; increased cellular accumulation and retention of a drug compound, to improve their therapeutic and diagnostic value, comprising linking the compound to one or more phosphonate groups
11/17/2005US20050256074 Methods and compositions for regulating lymphocyte activity
11/17/2005US20050256073 Immunostimulatory viral RNA oligonucleotides
11/17/2005US20050256070 Adjuvant
11/17/2005US20050256069 IRNA agents with biocleavable tethers
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256065 Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
11/17/2005US20050256064 9-Desoxoerythromycin compounds as prokinetic agents
11/17/2005US20050256063 Crystal forms of azithromycin
11/17/2005US20050256062 A tablet of a crystalline form of azithromycin sesquihydrate or crystalline azithromycin monohydrate hemi-isopropanol solvate and a carrier or diluent; nuclear magnetic resonance spectrum analysis; bactericides; antiprotozoa agents; infections of humans, mammals, birds, fish; drug resistance
11/17/2005US20050256059 administering D-mannose for producing neurosalutary effect in a patient useful in treatment of neurological disorders, including retinal and optic nerve damage
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256049 Chimeric toxins for targeted therapy
11/17/2005US20050256048 Selective androgen receptor modulators and methods for their identification, design and use
11/17/2005US20050256038 Stable pharmaceutical compsition containing factor VIII
11/17/2005US20050256034 Dioxolane analogs for improved inter-cellular delivery
11/17/2005US20050256033 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/17/2005US20050256032 Polyoxyalkylene compound and method for making
11/17/2005US20050256031 Composition for relieving discomfort
11/17/2005US20050256030 Heterocyclic self-immolative linkers and conjugates
1 ... 4465 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 ... 7860